Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy

INTRODUCTION: Worldwide, many patients with HER2+ (human epidermal growth factor receptor 2-positive) early breast cancer (BC) do not receive adjuvant trastuzumab. Hazards of recurrence of these patients with respect to hormone receptor status of the primary tumor have not been described. METHODS: U...

Descripción completa

Detalles Bibliográficos
Autores principales: Strasser-Weippl, Kathrin, Horick, Nora, Smith, Ian E, O’Shaughnessy, Joyce, Ejlertsen, Bent, Boyle, Frances, Buzdar, Aman U, Fumoleau, Pierre, Gradishar, William, Martin, Miguel, Moy, Beverly, Piccart-Gebhart, Martine, Pritchard, Kathleen I, Lindquist, Deborah, Rappold, Erica, Finkelstein, Dianne M, Goss, Paul E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4423419/
https://www.ncbi.nlm.nih.gov/pubmed/25888246
http://dx.doi.org/10.1186/s13058-015-0568-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4423419/
https://www.ncbi.nlm.nih.gov/pubmed/25888246
http://dx.doi.org/10.1186/s13058-015-0568-1

Ejemplares similares